A potential therapeutic combination for treatment of COVID-19: Synergistic effect of DPP4 and RAAS suppression
- Authors
- Phyu Phyu Khin; Cha, Seon-Heui; Jun, Hee-Sook; Lee, Jong Han
- Issue Date
- Nov-2020
- Publisher
- Churchill Livingstone
- Keywords
- Angiotensin converting enzyme-2; Coronavirus SARS-CoV-2; Dipeptidyl peptidase-4; Renin–angiotensin–aldosterone system
- Citation
- Medical Hypotheses, v.144
- Journal Title
- Medical Hypotheses
- Volume
- 144
- URI
- https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/79739
- DOI
- 10.1016/j.mehy.2020.110186
- ISSN
- 0306-9877
- Abstract
- COVID-19, caused by the novel coronavirus SARS-CoV-2, is an abbreviated name for coronavirus disease 2019. COVID-19 became a global pandemic in early 2020. It predominantly affects not only the upper and lower respiratory tract, but also multiple organs, including the kidney, heart, and brain. The mortality of COVID-19 patients is high in men and in elderly patients with age-related diseases such as hypertension and diabetes. The angiotensin converting enzyme-2 (ACE-2), a component in the renin–angiotensin–aldosterone system (RAAS), plays as cell surface receptors for SARS-CoV-2. A recent study proved that coronavirus SARS-CoV-2 also uses dipeptidyl peptidase-4 (DPP4, also known as adenosine deaminase complexing protein 2, CD26) as a co-receptor when entering cells. In addition, DPP4 is also implicated in the regulation of the immune response. Thus, the combination of DPP4 inhibition and suppression of ACE-2/RAAS may be a novel therapeutic strategy for combating this pandemic. © 2020
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 약학대학 > 약학과 > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.